Preparation method and application of calcium phosphate nano-drug for dual targeting of tumor cells and tumor-associated fibroblasts

siCXCR4 and HCPT were delivered to triple-negative breast cancer tissue through HA-modified calcium phosphate nanodrug vector. Targeted delivery using CD44 receptors successfully blocked the CXCL12/CXCR4 signaling axis, solving the target in triple-negative breast cancer treatment Sex and side effects problems significantly inhibit the proliferation and invasion of tumor cells.

CN118987251APending Publication Date: 2024-11-22FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411092393.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Triple-negative breast cancer lacks effective targeted treatment methods. The existing drugs are distributed throughout the body and have poor efficacy and have great side effects. The CXCL12/CXCR4 signaling axis blocking effect of tumor-related fibroblasts is not strong, making it difficult to effectively inhibit the migration of tumor cells. and invasion.

Method used

Using HA-modified calcium phosphate nanodrug carrier, siCXCR4 and HCPT are co-delivered to tumor tissues, and targeted delivery through CD44 receptors. siCXCR4 silencing CXCR4 protein, HCPT strongly kills tumor cells, and synergistically blocks the CXCL12/CXCR4 signaling axis. Inhibit tumor proliferation, migration and invasion.

Benefits of technology

Two-way blockade of triple-negative breast cancer cells and CAFs was achieved, which significantly inhibited the proliferation, migration and invasion of tumor cells, improved the therapeutic effect, and reduced the toxic side effects of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987251A_ABST
    Figure CN118987251A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a calcium phosphate nano-drug for dual targeting of tumor cells and tumor-related fibroblasts. The dual-targeting calcium phosphate nano-drug is prepared from the following components: siCXCR4, HCPT, anhydrous calcium chloride, disodium hydrogen phosphate, sodium hyaluronate and DEPC (diethylpyrocarbonate) water. The siCXCR4 and the HCPT are ingeniously loaded on a carrier calcium phosphate at the same time through an electrostatic adsorption method, a complexation reaction and a coprecipitation method, and efficient co-loading of the siCXCR4 and the HCPT is achieved. After S / HCPT (at) CaP / HA is taken by tumor cells and tumor-related fibroblasts, CXCR4 protein in 4T1 cells is effectively silenced (the silencing efficiency is 69.1%), and HCPT can powerfully kill the tumor cells and the tumor-related fibroblasts. The siCXCR4 and the HCPT perform respective functions and respective responsibilities, cooperatively and bidirectionally block a CXCL12 / CXCR4 signal axis, inhibit proliferation, migration and invasion of in-situ triple-negative breast cancer cells, improve an immune microenvironment, realize a double-targeting treatment effect of two birds in one stone, and improve a treatment effect of the in-situ triple-negative breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biopharmaceuticals and relates to a novel high-efficiency targeted drug delivery system for treating in situ triple-negative breast cancer. Background Art

[0002] In recent years, the incidence and mortality of breast cancer have been increasing year by year. The latest cancer burden data show that the incidence of breast cancer ranks first in the world and the mortality rate ranks second. Triple-negative breast cancer (TNBC) is a type of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Compared with other types of breast cancer, it is the most malignant and invasive, often occurs in young women, is prone to early metastasis, has a high recurrence rate, and has a very poor prognosis. It is the most lethal type of breast cancer. Surgical resection is the first choice for TNBC treatment, but because TNBC patients are relatively young, surgical resection will cause great psychological burden on patients on the one hand, and on the other hand, it is prone to recurrence and metastasis. Chemotherapy drugs have no specific targeting, are distributed throughout the body after administration, have poor efficacy and large side effects. Since TNBC hormone receptors and growth factor receptors are both negative, molecular targeted therapy is ineffective for it. PD-1 / PD-L1 inhibitors are immune checkpoint inhibitors approved by the FDA in recent years for the treatment of TNBC. They have significant clinical effects and significantly fewer side effects than traditional treatments. However, they are only effective for patients who are PD-L1 positive, and there are individual differences in the expression of PD-L1. According to clinical data, only about 20% of patients can produce an immune response. Therefore, conducting research on new treatment strategies for TNBC has important scientific significance and clinical application value.

[0003] Studies have shown that the chemokine CXCL12 secreted by carcinoma-associated fibroblasts (CAFs) can drive the CXCL12 / CXCR4 signaling axis and promote the migration and invasion of tumor cells. This suggests that inhibiting the activity of CAFs can reduce the secretion of CXCL12, block the CXCL12 / CXCR4 signaling axis, and inhibit the migration and invasion of tumor cells. CXCR4 is a specific receptor for CXCL12, and CXCR4 expression is higher in TNBC tissues compared with non-TNBC. This suggests that silencing CXCR4 protein using CXCR4-specific small interfering RNA (siCXCR4) can also block the CXCL12 / CXCR4 signaling axis and inhibit the migration and invasion of tumor cells. Therefore, if silencing CXCR4 protein in tumor cells while inhibiting the activity of CAFs can bidirectionally block the CXCL12 / CXCR4 signaling axis, doubling the inhibitory effect on tumor cell migration and invasion. However, blocking only the CXCL12 / CXCR4 signaling axis cannot effectively kill tumor cells and CAFs and inhibit their proliferation. Therefore, a strong cytotoxic drug is needed to be co-delivered with siCXCR4 to triple-negative breast cancer tissues to effectively kill tumor cells and CAFs and synergistically exert the effects of antigenic sites on the proliferation, migration and invasion of triple-negative breast cancer.

[0004] Hydroxycamptothecin (HCPT) is a trace alkaloid isolated and extracted from Camptotheca acuminata. It is a strong cytotoxic drug. Its mechanism of action is to form a stable covalent compound by binding to the DNA topoisomerase 1 / single-stranded DNA complex, inhibiting the unwinding and reconnection of the DNA chain, inducing DNA chain breakage, and ultimately leading to cell apoptosis. The combination of siCXCR4 and HCPT is a new strategy for the treatment of triple-negative breast cancer. However, siCXCR4 is easily degraded in the blood circulation, and HCPT is lipid- and water-insoluble. In clinical practice, it can only be used in the form of sodium salt with an efficacy of only 10-20% of the original structure. It has great toxic and side effects, and often causes severe bone marrow suppression after chemotherapy. Therefore, a suitable carrier is needed to deliver siCXCR4 and HCPT to tumor tissues to effectively exert anti-tumor proliferation, migration and invasion effects while reducing toxic and side effects.

[0005] Calcium phosphate (CaP) is an excellent delivery carrier for small interfering RNA, with the characteristics of high transfection efficiency, good biocompatibility, and biodegradability. CaP is also pH-sensitive and easily dissolved in the slightly acidic environment of tumor cell lysosomes. Using CaP as a carrier to load small interfering RNA can prevent the small interfering RNA from being degraded in the blood circulation. Since the HCPT structure contains a lactone ring, the lactone ring opens under alkaline conditions, exposing the ability to bind CaP. 2+The carboxyl group of CaP is bound to the HCPT, thereby cleverly loading HCPT. The open-ring HCPT can be further converted into the lipid-type HCPT with anti-tumor activity in the acidic microenvironment of tumor tissue. Therefore, the present invention uses CaP as a carrier to load siCXCR4 and HCPT at the same time to treat in situ triple-negative breast cancer. However, CaP is prone to aggregation and is unstable during preparation, and its distribution in the body is non-specific. Studies have found that when CaP is prepared, the addition of CaP can bind 2+ Ionic groups such as drugs or carriers containing carboxyl or phosphate groups can increase the stability of CaP nanoparticles.

[0006] Hyaluronic acid (HA) contains a large number of carboxyl groups that can bind Ca 2+ , forming stable CaP nanoparticles. In addition, HA is also a specific ligand for the CD44 receptor, which can improve the targeting of CaP nanoparticles. Our laboratory also found that CD44 is highly expressed in both 4T1 cells and CAFs. This suggests that if HA is modified on the CaP carrier, it can not only stabilize CaP, but also deliver drugs to tumor cells and CAFs through receptor-ligand binding, achieving dual-targeted therapeutic effects.

[0007] Based on the above research background, we constructed HA-modified co-loaded siCXCR4 and HCPT calcium phosphate nanodrugs (S / HCPT@CaP / HA). Through the targeting effect of HA, siCXCR4 and HCPT were co-delivered to triple-negative breast cancer cells and CAFs. HCPT can effectively kill triple-negative breast cancer cells and CAFs, reduce the proliferation of triple-negative breast cancer cells and the secretion of CXCL12. At the same time, siCXCR4 can silence the CXCR4 protein in triple-negative breast cancer cells. siCXCR4 and HCPT synergistically block the CXCL12 / CXCR4 signaling axis in both directions, inhibiting the proliferation, migration and invasion of triple-negative breast cancer in situ. Summary of the invention

[0008] The purpose of the present invention is to provide a preparation method and application of a calcium phosphate nanodrug that dual-targets tumor cells and tumor-associated fibroblasts. By modifying HA on a calcium phosphate carrier co-loaded with siCXCR4 and HCPT, the stability of the calcium phosphate nanodrug is improved, and siCXCR4 and HCPT are co-delivered to triple-negative breast cancer cells and CAFs through the CD44 receptor highly expressed in triple-negative breast cancer cells and CAFs. siCXCR4 can silence the CXCR4 protein in triple-negative breast cancer cells, and HCPT can potently kill triple-negative breast cancer cells and CAFs, reducing the secretion of CXCL12. siCXCR4 and HCPT each perform their duties and responsibilities, and synergistically block the CXCL12 / CXCR4 signal axis in both directions, inhibit the proliferation, migration and invasion of in situ triple-negative breast cancer cells, and achieve a "one stone, two birds" dual-targeted therapeutic effect, thereby improving the therapeutic effect of in situ triple-negative breast cancer.

[0009] The technical scheme of the present invention is: a preparation method of a calcium phosphate nanomedicine dual-targeting tumor cells and tumor-associated fibroblasts, wherein the dual-targeting calcium phosphate nanomedicine is composed of siCXCR4, HCPT, anhydrous calcium chloride, disodium hydrogen phosphate, sodium hyaluronate and DEPC water.

[0010] The preparation method is as follows: using CaP as a carrier material, negatively charged siCXCR4 and positively charged calcium ions are electrostatically adsorbed to form a complex containing siCXCR4 and calcium; under weakly alkaline conditions, the lactone ring in the HCPT structure is opened, and the excess calcium ions in the complex are complexed with the carboxyl groups on the open-ring HCPT structure to form a complex containing siCXCR4, calcium and HCPT; finally, using HA as a stabilizer, the above complex is added to a mixed solution of HA and disodium hydrogen phosphate, incubated at 37°C for 30 minutes, and then the HA-modified co-loaded siCXCR4 and HCPT calcium phosphate nanodrug (S / HCPT@CaP / HA) is obtained by nanoprecipitation; the particle size of S / HCPT@CaP / HA is 267.8nm, the potential is -20.4mV, and the HCPT loading is 14.3%.

[0011] Flow cytometry was used to investigate the targeting of S / HCPT@CaP / HA to triple-negative breast cancer cells (4T1 cells) and CAFs in mice; MTT method was used to investigate the effect of S / HCPT@CaP / HA on the proliferation of 4T1 cells and CAFs; in vivo imaging was used to observe the targeting of S / HCPT@CaP / HA to triple-negative breast cancer tissues; finally, the inhibitory effect of S / HCPT@CaP / HA on the proliferation, migration and invasion of in situ triple-negative breast cancer cells was investigated at the animal level. The effects and mechanisms of S / HCPT@CaP / HA in the treatment of in situ triple-negative breast cancer were elucidated in multiple ways.

[0012] The innovation of the present invention lies in:

[0013] 1. Using CaP as the carrier material, negatively charged siCXCR4 and positively charged calcium ions are adsorbed by electrostatic adsorption to form a complex containing siCXCR4 and calcium. Then, under weakly alkaline conditions, the open-ring HCPT reacts with the excess calcium ions in the above complex to form a complex of HCPT and calcium. Finally, using HA as a stabilizer, the above mixture is added to a mixed solution of HA and disodium hydrogen phosphate for co-precipitation to obtain HA-modified calcium phosphate nanodrugs co-loaded with siCXCR4 and HCPT (S / HCPT@CaP / HA), achieving efficient co-loading of siCXCR4 and HCPT.

[0014] 2. HA can not only be used as a stabilizer, but also as a target to improve the targeting of S / HCPT@CaP / HA. HA is a specific ligand for the CD44 receptor. After S / HCPT@CaP / HA is injected into the blood intravenously, it can be targeted into the cell through the CD44 receptor highly expressed in triple-negative breast cancer cells and CAFs, and release siCXCR4 and open-ring HCPT in the acidic environment of the lysosome. siCXCR4 blocks the CXCL12 / CXCR4 signaling axis by silencing the CXCR4 protein in tumor cells. The open-ring HCPT is further acidified into a lactone-type HCPT with anti-tumor activity. While effectively killing tumor cells, it inhibits the activity of CAFs and reduces the secretion of CXCL12. It cooperates with siCXCR4 to bidirectionally block the CXCL12 / CXCR4 signaling axis, inhibiting the proliferation, migration and invasion of triple-negative breast cancer cells.

[0015] 3. In this study, siCXCR4 and HCPT were cleverly loaded onto the CaP carrier simultaneously through electrostatic adsorption, complexation reaction and co-precipitation. No organic solvents were used in the preparation process. The carrier material has good biocompatibility, high safety, strong production controllability, and is easy for clinical transformation. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 is the particle size distribution (DLS) graph of S / HCPT@CaP / HA;

[0017] Figure 2 is the potential distribution diagram of S / HCPT@CaP / HA;

[0018] Figure 3 is the agarose gel electrophoresis experiment to investigate the loading of siCXCR4 in S / HCPT@CaP / HA;

[0019] Figure 4 is the thermogravimetric analysis of S / HCPT@CaP / HA;

[0020] Figure 5 The release of siCXCR4 in S / HCPT@CaP / HA under different pH conditions was observed by agarose gel electrophoresis blocking experiment;

[0021] Figure 6 The release of HCPT from S / HCPT@CaP / HA under different pH conditions was investigated by UPLC, n=3, Mean±SD, * p<0.05, ** p<0.01;

[0022] Figure 7 Flow cytometry was used to investigate the uptake of cy5-S / HCPT@CaP / HA by 4T1 cells and the effect of HA on the uptake of cy5-S / HCPT@CaP / HA by 4T1 cells; A: Flow cytometric graphs of cy5-S / HCPT@CaP / HA uptake by 4T1 cells at different time points; B: Statistical results of cy5 fluorescence intensity in Figure A; C: Flow cytometric graphs of the effect of different concentrations of HA on the uptake of cy5-S / HCPT@CaP / HA by 4T1 cells; D: Statistical results of cy5 fluorescence intensity in Figure C, n=3, * p<0.05, ** p<0.01;

[0023] Figure 8 Flow cytometry was used to investigate the uptake of cy5-S / HCPT@CaP / HA by CAFs and the effect of HA on the uptake of cy5-S / HCPT@CaP / HA by CAFs; A: Flow cytometric graphs of cy5-S / HCPT@CaP / HA uptake by CAFs at different time points; B: Statistical results of cy5 fluorescence intensity in Figure A; C: Flow cytometric graphs of the effect of different concentrations of HA on the uptake of cy5-S / HCPT@CaP / HA by CAFs; D: Statistical results of cy5 fluorescence intensity in Figure C, n=3, ** p<0.01;

[0024] Fig. 9 Western blot experiment to investigate the silencing effect of S / HCPT@CaP / HA on CXCR4 protein in 4T1 cells, n=3, Mean±SD, * p<0.05, ** p<0.01;

[0025] Fig.10 MTT experiment to investigate the inhibitory effect of S / HCPT@CaP / HA on the proliferation of 4T1 cells and CAFs, n=6, Mean±SD, * p<0.05, ** p<0.01;

[0026] Fig.11Transwell experiment to investigate the effect of S / HCPT@CaP / HA on the migration ability of 4T1 cells under the co-culture condition of 4T1 cells and CAFs; A: Crystal violet staining to observe the migration of 4T1 cells to the receptor pool; B: Relative migration rate statistics n=3, Mean±SD, ** p<0.01;

[0027] Fig.12 The effect of S / HCPT@CaP / HA on the invasion ability of 4T1 cells under the condition of co-culture of 4T1 cells and CAFs was investigated by Transwell experiment; A: Crystal violet staining was used to observe the migration of 4T1 cells into the receptor pool; B: Statistical results of relative invasion rate n=3, Mean±SD, ** p<0.01;

[0028] Fig.13 The in vivo imaging device was used to observe the distribution of S / HCPT@CaP / HA in various organs and tumor tissues of tumor-bearing mice;

[0029] Fig.14 The inhibitory effect of S / HCPT@CaP / HA on the growth of in situ triple-negative breast cancer; A: tumor tissue photo; B: tumor volume change; C: tumor tissue weight; n = 8, Mean ± SD, ** p<0.01;

[0030] Fig.15 Western blot experiment to investigate the silencing effect of S / HCPT@CaP / HA on CXCR4 protein in in situ triple-negative breast cancer tissues; n=3, Mean±SD, * p<0.05, ** p<0.01;

[0031] Fig.16 Western blot experiments were performed to investigate the effects of S / HCPT@CaP / HA on the expression of migration and invasion-related proteins in in situ triple-negative breast cancer tissues; A: Western blot images; B: semi-quantitative statistical results n=3, Mean±SD, * p<0.05, ** p<0.01. DETAILED DESCRIPTION

[0032] 1 Research Methods

[0033] 1.1 Preparation of HA-modified calcium phosphate nanoparticles co-loaded with siCXCR4 and HCPT

[0034] Accurately weigh 22 mg of anhydrous calcium chloride, dissolve it in 4 mL of DEPC water, and set aside; accurately weigh 143 mg of disodium hydrogen phosphate, add 10 mL of DEPC water (pH 9) and ultrasonically dissolve it, and set aside; accurately weigh 40 mg of HA, and after fully dissolving it, form a HA / disodium hydrogen phosphate mixed solution, and set aside; accurately weigh 4 mg of HCPT, dissolve it in 4 mL of DEPC water (pH 9), and set aside; take 1OD of siCXCR4, centrifuge it to make siCXCR4 sink to the bottom of the tube, add 62.5 mL of DEPC water, vortex for 1 minute to fully dissolve siCXCR4, and set aside. Accurately measure 15 μL of calcium chloride solution and siCXCR4 solution respectively, mix well, add 30 μL of HCPT solution and mix well, finally add 15 μL of HA and disodium hydrogen phosphate mixed solution, mix well, let stand in a 37°C float box for 30 minutes, and finally centrifuge in a low-temperature high-speed centrifuge for 10 minutes (4°C, 12000rpm), discard the supernatant, collect the precipitate and resuspend it in DEPC water to obtain S / HCPT@CaP / HA.

[0035] 1.2 Characterization of S / HCPT@CaP / HA

[0036] 1.2.1 Particle size, zeta potential and polydispersity

[0037] Take an appropriate amount of S / HCPT@CaP / HA, dilute it with 1 mL of deionized water, vortex it to disperse it evenly, and use a dynamic laser particle size analyzer to measure the particle size, zeta potential and polydispersity index (PDI) of S / HCPT@CaP / HA.

[0038] 1.2.2 Loading of siCXCR4 and HCPT on S / HCPT@CaP / HA

[0039] Agarose gel electrophoresis was used to investigate the loading of siCXCR4 on S / HCPT@CaP / HA. S / HCPT@CaP / HA with different calcium-phosphorus ratios (Ca / P were 31.2, 12.8, 6.4, 3.2, and 1.6, respectively) was prepared, and the supernatant was taken for testing after centrifugation. Accurately weigh 600 mg of agarose gel powder and dissolve it in 40 mL of TBE electrophoresis buffer and dissolve it by microwave heating. Add 4 μL of gelred while hot and shake well, pour it into the set-up device and let it stand for 25 minutes. Transfer the agarose gel to the electrophoresis tank and add TBE buffer to cover the surface. Pipette 16 μL of the sample to be tested, add 3 μL of loading buffer to each sample to be tested, mix well, and then load it. Electrophoresis was performed at 80 V for 30 minutes, and the amount of siCXCR4 in the supernatant of S / HCPT@CaP / HA was observed by an imager to evaluate the loading of siCXCR4.

[0040] Weigh 5 mg S / HCPT@CaP / HA, dissolve in 0.1 mL hydrochloric acid solution (0.01 M) and etch for 30 minutes, dilute to 1 mL with deionized water (pH 9), inject 10 μL of sample, record the peak area, and calculate the HCPT loading. The chromatographic column is Diamonsil C 18 Chromatographic column (250mm×4mm, 5μm); mobile phase: water / methanol=40 / 60 (v / v), pH adjusted to 5.5 with 1% glacial acetic acid and triethylamine; detection wavelength is 384nm; flow rate is 1.0mL / min; column temperature is 30℃.

[0041] 1.2.3 Thermogravimetric analysis

[0042] CaP, @HA-CaP, HCPT@HA-Ca and S / HCPT@CaP / HA were prepared. 2.5 mg of each group of drugs and HCPT raw material were accurately weighed and placed in an alumina crucible. The relevant parameters (scanning temperature range: 0-700°C, nitrogen protection state, heating rate: 10°C / min) were set for thermogravimetric analysis. The drug components were analyzed by examining the relationship between the mass of each group of drugs and the temperature change.

[0043] 1.2.4 pH response characteristics of S / HCPT@CaP / HA

[0044] 1.2.4.1 Observation of the release of siCXCR4 in S / HCPT@CaP / HA under different pH conditions by agarose gel electrophoresis

[0045] S / HCPT@CaP / HA was placed in DEPC water with different pH values, and centrifuged for 10 minutes (4°C, 12000rpm) at 0, 0.5, 2, 4, 8, and 24 hours, and the precipitate was collected. 10 μL HCl (0.01M) was added to the precipitate and mixed, and the mixture was allowed to stand at room temperature for 3 hours to fully release siCXCR4 from the precipitate. 3 μL RNA loading buffer (5×) was added and mixed, and then added to the agarose gel sample well for electrophoresis at 100V for 30 minutes. The release of siCXCR4 under different pH conditions was observed by gel imaging.

[0046] 1.2.4.2 Observation of HCPT release from S / HCPT@CaP / HA under different pH conditions by UPLC

[0047] S / HCPT@CaP / HA was encapsulated in a dialysis bag. The external liquid was 100 mL of distilled water with different pH values. 1 mL of the external liquid was collected at different time points, and the same volume of solution was added to the external liquid. The UPLC method was used to detect the release amount of HCPT.

[0048] 1.3 Flow cytometry observation of cy5-S / HCPT@CaP / HA uptake by 4T1 cells and CAFs

[0049] 4T1 cells and NIH-3T3 cells were cultured in an incubator at 37°C and 5% CO2. When the 4T1 cell confluence reached 70-80%, the cell culture fluid was collected, centrifuged, filtered, and cell debris were removed to obtain 4T1 cell conditioned medium (4T1-CM). The old culture medium of NIH-3T3 cells was discarded and replaced with a mixed solution of 4T1-CM and DMEM complete culture medium (V 4T1-CM :V DMEM =1:1), stimulate NIH-3T3 cells for 48 h to form CAFs. 4T1 cells and CAFs were cultured at a rate of 1×10 5 The density of 4T1 cells / mL was added into a 12-well plate (1 mL / well). After culturing for 24 h, serum-free culture medium containing cy5-labeled S / HCPT@CaP / HA (cy5-S / HCPT@CaP / HA) was added to each well. After incubation for 1 h, 3 h, and 6 h, the cells were collected and the fluorescence intensity of cy5 in 4T1 cells and CAFs was detected by flow cytometry to evaluate the uptake capacity of 4T1 cells and CAFs for cy5-S / HCPT@CaP / HA. In addition, according to the above steps, different concentrations of HA solution (0.1 mg / mL, 1 mg / mL, 10 mg / mL) were added to 4T1 cells and CAFs, and the 4T1 cells and CAFs were first reacted for 2 h. Then, serum-free culture medium containing cy5-S / HCPT@CaP / HA was added. After incubation for 6 h, the fluorescence intensity of cy5 in 4T1 cells and CAFs was detected by cell flow cytometry to evaluate the effect of HA on the uptake of cy5-S / HCPT@CaP / HA by 4T1 cells and CAFs.

[0050] 1.4S / HCPT@CaP / HA silencing effect on CXCR4 protein in 4T1 cells

[0051] 4T1 cells were cultured at 1×10 6 The cells were inoculated at a density of 100 / mL in a 96-well plate (2 mL / well). After culturing in a 37°C, 5% CO2 incubator for 24 hours, the old culture medium was discarded and replaced with 2 mL of serum-free culture medium containing HCPT, N / HCPT@CaP / HA, S@CaP / HA and S / HCPT@CaP / HA, respectively. The serum-free culture medium without any drug was used as a control, and 3 replicates were set for each group. After continuing to culture for 48 hours, the cells were collected and the silencing effect of S / HCPT@CaP / HA on CXCR4 protein in 4T1 cells was investigated by western blot.

[0052] 1.5 In vitro antiproliferation, migration and invasion effects of S / HCPT@CaP / HA 1.5.1 MTT assay to investigate the inhibitory effect of S / HCPT@CaP / HA on the proliferation of 4T1 cells and CAFs

[0053] 4T1 cells and CAFs were cultured at 5×10 4 The cells were inoculated at a density of 100 μL / mL in a 96-well plate (0.2 mL / well). After culturing in a 37°C, 5% CO2 incubator for 24 hours, 200 μL of @CaP / HA, N@CaP / HA, S@CaP / HA, HCPT, N / HCPT@CaP / HA and S / HCPT@CaP / HA at different concentrations were added. After culturing for 48 hours, 20 μL (5 mg / mL) of MTT solution was added to each well and incubated for another 4 hours. 150 μL of DMSO was added to each well, and the absorbance of each well solution was measured at 490 nm using an enzyme-linked immunosorbent assay to calculate the cell survival rate.

[0054] 1.5.2 Cell migration assay

[0055] 4T1 cells were cultured at 1×10 6 CAFs were seeded at a density of 1×10 6 The cells were inoculated at a density of 100 / mL in the Transwell receptor pool (0.6mL / well). After 24 hours, the culture medium containing HCPT, N / HCPT@CaP / HA, S@CaP / HA, and S / HCPT@CaP / HA was added to the donor pool and the receptor pool at the same time. The culture medium without any drug was used as the control. Three replicate wells were set up in each group and incubated for another 48 hours. The donor pool and the receptor pool were separated, and the donor pool was rinsed 3 times with PBS, fixed in 4% paraformaldehyde solution for 15 minutes, rinsed again with PBS 3 times, and stained in 0.1% crystal violet stain for 15 minutes. The cells on the back of the donor pool were observed under an inverted microscope and photographed and recorded. 0.6mL of glacial acetic acid solution (33%) was added to each well. After shaking, the absorbance value was detected at 570nm using an enzyme-linked immunosorbent assay to calculate the relative migration rate of the cells. Relative migration rate of cells (%) = (absorbance value of the drug group / absorbance value of the control group) × 100%

[0056] 1.5.3 Cell invasion assay

[0057] (1) Preparation of BD gel. Dilute BD gel with serum-free 1640 culture medium at a ratio of 9:1 under ice bath conditions, add 40 μL to each well of the Transwell donor cell, and place in an incubator for 5 h to allow the BD gel to solidify.

[0058] (2) 4T1 cells were cultured at 1×10 6CAFs were seeded at a density of 1×10 / mL in a Transwell donor pool (0.3 mL / well) containing BD gel. 6 The cells were inoculated at a density of 100 / mL in the Transwell receptor pool (0.6mL / well). After 24 hours, the culture medium containing HCPT, N / HCPT@CaP / HA, S@CaP / HA, and S / HCPT@CaP / HA was added to the donor pool and the receptor pool at the same time. The culture medium without any drug was used as the control. Three replicate wells were set up in each group and incubated for another 48 hours. The donor pool and the receptor pool were separated, and the donor pool was rinsed 3 times with PBS, fixed in 4% paraformaldehyde solution for 15 minutes, rinsed again with PBS 3 times, and stained in 0.1% crystal violet stain for 15 minutes. The cells on the back of the donor pool were observed under an inverted microscope and photographed and recorded. 0.6mL of glacial acetic acid solution (33%) was added to each well. After shaking, the absorbance value was detected at 570nm using an enzyme-linked immunosorbent assay to calculate the relative cell invasion rate. Relative cell invasion rate (%) = (absorbance value of the drug group / absorbance value of the control group) × 100%

[0059] 1.6 Establishment of an orthotopic triple-negative breast cancer mouse model

[0060] Luciferase labeled 4T1 cells (Luc-4T1) were cultured at a density of 2×10 6 The cell suspension of 100 μL / mL was dispensed into 1.5 mL EP tubes and stored in an ice bath for later use. BALB / c female mice were taken, the abdomen was depilated, and 4% chloral hydrate was injected intraperitoneally at a dose of 0.2 mL / 20 g to anesthetize the mice, and 200 μL of the cell suspension was implanted into the fourth mammary fat pad of the mice.

[0061] 1.7S / HCPT@CaP / HA targeting in situ triple-negative breast cancer tissue

[0062] Take the above-constructed orthotopic triple-negative breast cancer mouse model mice and wait for the tumor to grow to 100mm 3 At the same time, cy5-S / HCPT@CaP / HA (naked cy5-siCXCR4 and free HCPT were used as controls) were injected into the tail vein. The mice were killed after 6h, 12h, and 24h, and the brain, heart, liver, spleen, lung, and kidney tissues were obtained. The distribution of cy5-S / HCPT@CaP / HA in the brain, heart, liver, spleen, lung, and kidney tissues of tumor-bearing mice was observed using an in vivo imaging device.

[0063] Effects of 1.8S / HCPT@CaP / HA on proliferation, migration and invasion of triple-negative breast cancer in vivo

[0064] Luc-4T1 cells were inoculated for 7 days and then injected into the tail vein, once every 3 days for 4 times in a row, to investigate the therapeutic effect of S / HCPT@CaP / HA on in situ triple-negative breast cancer. The experimental animals were divided into groups and the dosage was set as follows: model group, free HCPT group, N / HCPT@CaP / HA group, S@CaP / HA group, S / HCPT@CaP / HA low-dose group (siCXCR4: 0.3 mg / kg HCPT: 1.3 mg / kg) and S / HCPT@CaP / HA high-dose group (siCXCR4: 1.0 mg / kg HCPT: 3.9 mg / kg), 8 animals in each group.

[0065] Tumor volume (mm) was recorded every 3 days. 3 ), and observe the changes in tumor volume over time (days). Tumor volume = maximum tumor diameter (mm) × shortest tumor diameter (mm) 2 / 2, evaluate the inhibitory effect of S / HCPT@CaP / HA on the proliferation of in situ triple-negative breast cancer in mice.

[0066] After the treatment, the mice were killed by dislocation, and the in situ triple-negative breast cancer tissues were isolated and weighed. Western blot experiments were used to investigate the expression of CXCR4 protein and migration and invasion-related proteins (MMP-9, E-cadherin, N-cadherin) in in situ triple-negative breast cancer tissues, and to evaluate the inhibitory effect of S / HCPT@CaP / HA on the migration and invasion of in situ triple-negative breast cancer in mice.

[0067] 2 Experimental results

[0068] 2.1 Characterization and pH response characteristics of S / HCPT@CaP / HA

[0069] The average particle size of S / HCPT@CaP / HA was 250.33±15.74nm, and the average dispersion index was 0.29±0.03( Figure 1 ), zeta potential is -20.4mV( Figure 2 ). When Ca / P was 12.8, siCXCR4 was almost completely loaded ( Figure 3). The drug loading of HCPT measured by UPLC was 14.3%. The results of thermogravimetric analysis showed that CaP dropped sharply at 50-240℃, and the mass of CaP sample decreased by about 12.5% ​​in the range of 50-700℃. Its maximum decomposition temperature appeared near (135±1)℃, at which time the sample lost weight the fastest, which was caused by the weight loss of CaP in the range of 50-240℃. HA lost weight twice at 250-650℃, and the maximum decomposition temperature appeared near (260±1)℃, at which time the sample lost weight the fastest. The weight loss range of @HA~CaP increased to around 300℃, the overall weight loss percentage increased to 32.5%, and two peaks appeared in the DTG curve, corresponding to two decomposition temperatures, indicating that CaP was modified by HA. The TG curve and DTG curve of HCPT raw material showed that HCPT dropped sharply at 270-600℃, and the maximum decomposition temperature appeared near (530±1)℃, at which time the sample lost weight the fastest. HCPT@CaP / HA drops sharply at 50-240℃, and a clear platform appears in the range of 320-420℃. With the increase of temperature, it drops sharply again between 320-420℃, and the overall weight loss percentage is about 45%. Compared with @CaP / HA, the continuous decline of TG curve is caused by the weight loss of HCPT, indicating that HCPT, HA and CaP coprecipitate ( Figure 4 ).

[0070] Agarose gel electrophoresis blocking experiment and UPLC method were used to investigate the release of siCXCR4 and HCPT under different pH environments. The results showed that in an acidic environment, siCXCR4 and HCPT were released more ( Figure 5-6 ). The above results show that the prepared S / HCPT@CaP / HA can achieve efficient loading of siCXCR4 and HCPT, has uniform particle size, and has pH-responsive drug release properties.

[0071] 2.2 Uptake of cy5-S / HCPT@CaP / HA by 4T1 cells and CAFs

[0072] Flow cytometry was used to detect the uptake of cy5-S / HCPT@CaP / HA by 4T1 cells and CAFs. Figure 7-8 As shown in the figure, both 4T1 cells and CAFs can effectively take up S / HCPT@CaP / HA in a time-dependent manner. As the concentration of HA increases, the amount of S / HCPT@CaP / HA taken up by 4T1 cells and CAFs decreases significantly, indicating that the early administration of HA can make HA compete with S / HCPT@CaP / HA for CD44 receptors on the surface of 4T1 cells and CAFs, thereby reducing the uptake of S / HCPT@CaP / HA by 4T1 cells and CAFs, and it is concentration-dependent.

[0073] 2.3S / HCPT@CaP / HA silencing effect on CXCR4 protein in 4T1 cells and its anti-proliferation, migration and invasion effects in vitro

[0074] like Fig. 9 As shown in the figure, S / HCPT@CaP / HA can effectively silence CXCR4 protein in 4T1 cells with a silencing efficiency of 69.1%. MTT results showed that the inhibitory effect of S@CaP / HA alone on 4T1 cells and CAFs was weak, and HCPT had good anti-proliferative activity. Compared with other drug treatment groups, S / HCPT@CaP / HA had the strongest inhibitory effect on 4T1 cells and CAFs ( Fig.10 ). 4T1 cells and CAFs were co-cultured in 24-well plates using Transwell chambers to investigate the effects of S / HCPT@CaP / HA on the migration and invasion of 4T1 cells. Figure 11-12 As shown in the results, HCPT, N / HCPT@CaP / HA, S@CaP / HA, and S / HCPT@CaP / HA could inhibit the migration and invasion of 4T1 cells to varying degrees, among which S / HCPT@CaP / HA had the strongest inhibitory effect on the migration and invasion of 4T1 cells.

[0075] 2.4S / HCPT@CaP / HA targeting in situ triple-negative breast cancer tissue

[0076] Cy5-labeled S / HCPT@CaP / HA was used to investigate the distribution of Cy5-S / HCPT@CaP / HA in mice by in vivo imaging. Fig.13 As shown, compared with the free drug group, S / HCPT@CaP / HA has stronger targeting and can selectively accumulate in triple-negative breast cancer tissues.

[0077] Effects of 2.5S / HCPT@CaP / HA on proliferation, migration and invasion of triple-negative breast cancer in vivo

[0078] From the statistical results of mouse tumor size, tumor volume change and tumor tissue weight, S / HCPT@CaP / HA can significantly inhibit the growth of in situ triple-negative breast cancer and has good in vivo antitumor activity ( Fig.14 ). Western blot was used to detect the expression of CXCR4 protein in in situ triple-negative breast cancer tissues. Fig.15As shown in the results, both the N / HCPT@CaP / HA and S@CaP / HA treatment groups were unable to silence the expression of CXCR4 protein in in situ triple-negative breast cancer tissues to a certain extent, while the expression of CXCR4 protein was the lowest after S / HCPT@CaP / HA treatment, indicating that S / HCPT@CaP / HA can bidirectionally block the CXCL12 / CXCR4 signaling axis and inhibit the migration and invasion of cancer cells. At the same time, western blot experiments were used to detect the expression of migration and invasion-related proteins (E-cadherin, N-cadherin, MMP-9) in in situ triple-negative breast cancer tissues to further evaluate the effect of S / HCPT@CaP / HA in reversing the epithelial-mesenchymal transition of in situ triple-negative breast cancer cells in mice and its inhibitory effect on extracellular matrix degradation. The results are shown in Fig.16 As shown in the figure, compared with the N / HCPT@CaP / HA and S@CaP / HA treatment groups, after S / HCPT@CaP / HA treatment, the expression of N-cadherin and MMP-9 proteins in the in situ triple-negative breast cancer tissues of mice was significantly reduced, and the expression of E-cadherin protein was significantly increased. The above results show that S / HCPT@CaP / HA can block the CXCL12 / CXCR4 signaling axis, increase the adhesion between triple-negative breast cancer cells, inhibit their detachment from tumor tissues, reverse epithelial-mesenchymal transition, and inhibit the degradation of extracellular matrix, thereby reducing the spread, migration and invasion of breast cancer cells.

[0079] 3 Conclusion

[0080] In summary, this study used CaP as a carrier material, and negatively charged siCXCR4 and positively charged calcium ions were electrostatically adsorbed to form a complex containing siCXCR4 and calcium. Then, under weak alkaline conditions, the open-ring HCPT and calcium ions reacted through a complexation reaction to form a complex of HCPT and calcium. Finally, HA was used as a stabilizer, and the above mixture was co-precipitated in a mixed solution of HA and inorganic phosphorus to prepare HA-modified calcium phosphate nanomedicines co-loaded with siCXCR4 and HCPT (S / HCPT@CaP / HA). HA can not only serve as a stabilizer, but also improve the targeting of S / HCPT@CaP. HA is a specific ligand for the CD44 receptor. After S / HCPT@CaP / HA is injected into the blood intravenously, it can be targeted into the cell through the CD44 receptor highly expressed in tumor cells and CAFs cells, and siCXCR4 and open-ring HCPT are released in the acidic environment of lysosomes. siCXCR4 blocks the CXCL12 / CXCR4 signaling axis by silencing the CXCR4 protein in tumor cells; the open-ring HCPT is further acidified into the lactone HCPT with anti-tumor activity. While the lactone HCPT exerts a strong killing effect on tumor cells, it inhibits the activity of CAFs and reduces the secretion of chemokine CXCL12. It cooperates with siCXCR4 to bidirectionally block the CXCL12 / CXCR4 signaling axis and inhibits the proliferation, migration and invasion of triple-negative breast cancer cells. In this study, siCXCR4 and HCPT were cleverly loaded onto the CaP carrier at the same time through electrostatic adsorption, complexation reaction and coprecipitation, achieving efficient co-loading of siCXCR4 and HCPT. No organic solvents are used in the preparation process. The carrier material has good biocompatibility, high safety, strong production controllability, and is easy for clinical transformation.

Claims

1. A method for preparing a calcium phosphate nanodrug that dual-targets tumor cells and tumor-associated fibroblasts, characterized in that The dual-target calcium phosphate nanomedicine is composed of siCXCR4, HCPT, anhydrous calcium chloride, disodium hydrogen phosphate, sodium hyaluronate and DEPC water; the preparation method is as follows: Using CaP as a carrier material, negatively charged siCXCR4 and positively charged calcium ions are electrostatically adsorbed to form a complex containing siCXCR4 and calcium; under weakly alkaline conditions, the lactone ring in the HCPT structure is opened, and the excess calcium ions in the complex are complexed with the carboxyl groups on the open-ring HCPT structure to form a complex containing siCXCR4, calcium and HCPT; finally, using HA as a stabilizer, the above complex is added to a mixed solution of HA and disodium hydrogen phosphate, incubated at 37°C for 30 minutes, and then the HA-modified co-loaded siCXCR4 and HCPT calcium phosphate nanodrug (S / HCPT@CaP / HA) is obtained by nanoprecipitation; the particle size of S / HCPT@CaP / HA is 267.8nm, the potential is -20.4mV, and the HCPT drug loading is 14.3%; After S / HCPT@CaP / HA is injected into the blood intravenously, it is targeted into the cells through the CD44 receptor highly expressed in tumor cells and CAFs cells, and siCXCR4 and open-ring HCPT are released in the acidic environment of lysosomes. SiCXCR4 effectively silences the CXCR4 protein in 4T1 tumor cells, thereby blocking the CXCL12 / CXCR4 signaling axis. The open-ring HCPT is further acidified into the lactone HCPT with anti-tumor activity. While the lactone HCPT exerts a strong killing effect on tumor cells, it inhibits the activity of CAFs and reduces the secretion of chemokine CXCL12. It cooperates with siCXCR4 to bidirectionally block the CXCL12 / CXCR4 signaling axis, inhibits the proliferation, migration and invasion of in situ triple-negative breast cancer cells, improves the immune microenvironment, achieves dual-targeted therapeutic effects, and improves the therapeutic effect of in situ triple-negative breast cancer.

2. Application of a calcium phosphate nanodrug that dual-targets tumor cells and tumor-associated fibroblasts in the preparation of drugs for the treatment of breast cancer.